ATE540685T1 - Wundheilende verwendung von sulfatierten depolymerisierten exopolysaccharidderivate - Google Patents

Wundheilende verwendung von sulfatierten depolymerisierten exopolysaccharidderivate

Info

Publication number
ATE540685T1
ATE540685T1 AT05775263T AT05775263T ATE540685T1 AT E540685 T1 ATE540685 T1 AT E540685T1 AT 05775263 T AT05775263 T AT 05775263T AT 05775263 T AT05775263 T AT 05775263T AT E540685 T1 ATE540685 T1 AT E540685T1
Authority
AT
Austria
Prior art keywords
derivatives
exopolysaccharide
molecular weight
epss
wound healing
Prior art date
Application number
AT05775263T
Other languages
English (en)
Inventor
Karim Senni
Farida Geuniche
Miriam Yousfi
Florence Fioretti
Gaston-Jacques Godeau
Sylvia Colliec-Jouault
Jacqueline Ratiskol
Corinne Sinquin
Gerard Raguenes
Anthony Courtois
Jean Guezennec
Original Assignee
Ifremer
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifremer, Univ Paris Descartes filed Critical Ifremer
Application granted granted Critical
Publication of ATE540685T1 publication Critical patent/ATE540685T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0666—Mesenchymal stem cells from hair follicles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT05775263T 2004-06-14 2005-06-06 Wundheilende verwendung von sulfatierten depolymerisierten exopolysaccharidderivate ATE540685T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406405A FR2871379B1 (fr) 2004-06-14 2004-06-14 Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese
PCT/FR2005/001379 WO2006003290A2 (fr) 2004-06-14 2005-06-06 Derives depolymerises sulfates d'exopolysaccharides (eps) preparation et utilisations

Publications (1)

Publication Number Publication Date
ATE540685T1 true ATE540685T1 (de) 2012-01-15

Family

ID=34946349

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05775288T ATE510546T1 (de) 2004-06-14 2005-06-06 Sulfierte depolymerisierte exopolysaccharidderivate, ihre herstellung und verwendungen
AT05775263T ATE540685T1 (de) 2004-06-14 2005-06-06 Wundheilende verwendung von sulfatierten depolymerisierten exopolysaccharidderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05775288T ATE510546T1 (de) 2004-06-14 2005-06-06 Sulfierte depolymerisierte exopolysaccharidderivate, ihre herstellung und verwendungen

Country Status (9)

Country Link
US (5) US20080131472A1 (de)
EP (2) EP1755620B1 (de)
JP (2) JP5148272B2 (de)
AT (2) ATE510546T1 (de)
AU (2) AU2005259078B2 (de)
CA (2) CA2570199C (de)
ES (2) ES2385088T3 (de)
FR (1) FR2871379B1 (de)
WO (2) WO2006003289A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894147B1 (fr) * 2005-12-07 2008-02-15 Ifremer Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus a des fins de regeneration et de protection du parodonte
JP2007204396A (ja) * 2006-01-31 2007-08-16 Pias Arise Kk マトリックスメタロプロテアーゼ−９及びエンドセリン−１の産生抑制剤、並びにその産生抑制剤を配合した炎症後色素沈着の予防・改善剤、化粧料
EP2265249B1 (de) * 2008-04-15 2018-08-29 Lucas Meyer Cosmetics Canada Inc. Kosmetische zusammensetzungen mit aus mikrobiellen matten abgeleiteten exopolysacchariden und verwendung davon
WO2010086696A1 (en) 2009-01-28 2010-08-05 Therapol Low-molecular-weight sulphated polysaccharides as candidates for anti-angiogenic therapy
FR2953217B1 (fr) 2009-11-27 2012-10-05 Ifremer Procede de depolymerisation de polysaccharides par broyage mecanique
CN101856658B (zh) * 2010-06-01 2011-09-07 云南大红山管道有限公司 一种长距离铁精矿管道软堵塞的疏通方法
FR2964014B1 (fr) * 2010-08-31 2013-04-05 Ifremer Nucleus enrobe d'un revetement filmogene aux proprietes antibacteriennes et cicatrisantes et procede d'obtention.
ES2390033B1 (es) 2010-11-30 2013-10-31 Lipotec S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas.
JP6100451B2 (ja) * 2011-01-18 2017-03-22 ヒノキ新薬株式会社 皮膚外用剤
ES2590752T3 (es) * 2011-03-18 2016-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Medios de diferenciación condrogénica y métodos para inducir la diferenciación condrogénica de células
ES2424294B1 (es) * 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP3146971A1 (de) * 2015-09-28 2017-03-29 Institut Francais de Recherche pour l'Exploitation de la Mer (IFREMER) Antimetastatisches derivat aus marinen bakteriellen exopolysacchariden und verwendungen davon
CN109069875B (zh) * 2016-01-07 2021-12-24 位于本-古里安大学之内盖夫技术与应用有限公司 产生免疫耐受反应的组合物和方法
CA3035642A1 (en) 2016-09-01 2018-03-08 Instituto De Biologia Molecular E Celular - Ibmc Cyanobacterium extracellular polymer, compositions and uses thereof
JP2023533383A (ja) 2020-07-02 2023-08-02 アンスティテュ・フランセ・ドゥ・レシェルシェ・プール・レクスプローテシオン・ドゥ・ラ・メール （イエフエルウメール） 海洋性細菌性エキソポリサッカライド誘導体及びムコ多糖症の処置におけるその使用
EP4112060A1 (de) 2021-07-01 2023-01-04 Institut Francais de Recherche pour l'Exploitation de la Mer (IFREMER) Niedermolekulare he800-exopolysaccharidderivate mit antikrebs-eigenschaften und ihre verwendungen
CN116731221B (zh) * 2023-06-26 2024-03-12 益得来(深圳)健康科技有限公司 一种多糖衍生物及其在制药中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102566A (en) * 1977-05-02 1978-07-25 Foster Grant Corporation Rimless spectacle
JPS58121799A (ja) * 1982-01-14 1983-07-20 Microbial Chem Res Found 多糖類ｍｐ−８６物質およびその製造法
IT1214609B (it) 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
FR2701488B1 (fr) * 1993-02-15 1995-05-05 Ifremer Bactéries du type Alteromonas, polysaccharides produits par ces bactéries, ose contenu dans ces polysaccharides et applications.
US6255296B1 (en) * 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
JP2986376B2 (ja) * 1995-06-16 1999-12-06 株式会社ホリカワ リムレス眼鏡におけるブリッジ及びリムレス眼鏡
US5985330A (en) * 1996-08-05 1999-11-16 Coastside Bio Resources Inhibition of angiogenesis by sea cucumber fractions
US5828307A (en) * 1996-09-23 1998-10-27 Phillips Petroleum Company Hydrocarbon gas monitor desk
FR2755142B1 (fr) * 1996-10-30 1999-01-15 Ifremer Souche bacterienne marine du genre alteromonas, exopolysaccharides hydrosolubles produits par cette souche, et leurs utilisations
US5847800A (en) * 1996-12-13 1998-12-08 Tachibana; Hideaki Lens holding mechanism of spectacles
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
FR2760022B1 (fr) 1997-02-25 1999-04-30 Ifremer Souche bacterienne marine du genre vibrio, polysaccharides hydrosolubles produits par cette souche, et leurs utilisations
FR2780063B1 (fr) * 1998-06-22 2001-07-13 Ifremer Polysaccharide purifie d'alteromonas macleodii et ses utilisations
US6024445A (en) * 1998-11-04 2000-02-15 Microvision Optical, Inc. Single point attachment of bridge and temples to eyeglass lenses
IT1302534B1 (it) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
FR2797768B1 (fr) * 1999-09-01 2003-06-13 Ifremer Utilisation d'un polysaccharide sulfate de bas poids moleculaire pour l'obtention d'un medicament actif contre la thrombose vasculaire
FR2811229B1 (fr) * 2000-07-04 2003-08-01 Ifremer Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus en cicatrisation osseuse
CA2489870A1 (en) * 2002-06-18 2003-12-24 Glycores 2000 S.R.L. Low molecular weight oversulfated polysaccharide
US7736636B2 (en) * 2003-02-12 2010-06-15 Shaker Mousa Method for treating occlusive vascular diseases & wound healing

Also Published As

Publication number Publication date
WO2006003290A3 (fr) 2006-05-04
ES2385088T3 (es) 2012-07-18
AU2005259078A2 (en) 2006-01-12
US20080131472A1 (en) 2008-06-05
CA2570224A1 (fr) 2006-01-12
FR2871379B1 (fr) 2006-09-29
AU2005259078A1 (en) 2006-01-12
ATE510546T1 (de) 2011-06-15
ES2367121T3 (es) 2011-10-28
US8598142B2 (en) 2013-12-03
EP1765366B1 (de) 2012-01-11
EP1755620A2 (de) 2007-02-28
FR2871379A1 (fr) 2005-12-16
JP5148272B2 (ja) 2013-02-20
US20070259833A1 (en) 2007-11-08
AU2005259078B2 (en) 2011-03-31
US7833990B2 (en) 2010-11-16
EP1755620B1 (de) 2011-05-25
EP1765366A2 (de) 2007-03-28
US20110245199A1 (en) 2011-10-06
WO2006003289A3 (fr) 2006-05-04
AU2005259077A1 (en) 2006-01-12
WO2006003290A2 (fr) 2006-01-12
JP2008502762A (ja) 2008-01-31
JP5154221B2 (ja) 2013-02-27
AU2005259077B2 (en) 2011-01-20
JP2008502763A (ja) 2008-01-31
US20140037597A1 (en) 2014-02-06
CA2570199A1 (fr) 2006-01-12
CA2570199C (fr) 2013-08-06
US9125883B2 (en) 2015-09-08
US20150344848A1 (en) 2015-12-03
WO2006003289A2 (fr) 2006-01-12
CA2570224C (fr) 2015-08-04
US10105393B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
ATE540685T1 (de) Wundheilende verwendung von sulfatierten depolymerisierten exopolysaccharidderivate
Shaughnessy et al. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria
Kim et al. Injectable hyaluronic acid–tyramine hydrogels for the treatment of rheumatoid arthritis
Kogan et al. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications
Mao et al. A preliminary study on chitosan and gelatin polyelectrolyte complex cytocompatibility by cell cycle and apoptosis analysis
Ballini et al. Esterified hyaluronic acid and autologous bone in the surgical correction of the infra-bone defects
Park et al. The possibility of microbial cellulose for dressing and scaffold materials
NO20052399D0 (no) Taksaner som er kovalent bundet til hyaluronsyre eller hyaluronsyrederivater.
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
NO20080240L (no) Sammensetninger av delvis deacetylerte kitinderivater
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
CA2969383C (en) Aminoacid-based composition for fibroelastin recovery in dermal connective tissues
Shuborna et al. Generation of novel hyaluronic acid biomaterials for study of pain in third molar intervention: a review
BR112014026088A2 (pt) produto de tratamento de tecidos, estojo, método de fabricação de um produto de tratamento de tecidos, método de tratamento, e uso do produto de tratamento de tecidos
NO20050244L (no) Epimeriserte derivater av K5-polysakkarid med en meget hoy grad av sulfatering
Schneider et al. Sulfated hyaluronan‐containing artificial extracellular matrices promote proliferation of keratinocytes and melanotic phenotype of melanocytes from the outer root sheath of hair follicles
DE60237039D1 (de) Verfahren zur behandlung von rosacea und telangiectasia
CY1119579T1 (el) Μεθοδος για τη θεραπεια διαταραχων αναπτυξης της τριχας, οπως η γυναικειου τυπου αλωπεκια και συνεπως χρησιμα σκευασματα
BRPI0416088A (pt) composição, sistema, e método de tratar condições tais como calcificação vascular
KR20160105969A (ko) N-탈황화된 글루코스아미노글리칸 유도체 및 약물로서의 용도
JP5911463B2 (ja) アスコルビン酸誘導体によるヒアルロン酸の生成を刺激するための方法及び組成物
EA032372B1 (ru) Комбинация гликозаминогликанов и циклодекстринов
EP3233041B1 (de) Kosmetisches verfahren zur milderung von falten
US20120328557A1 (en) Adhesive cell tissue gels
ATE374024T1 (de) Verwendung von 5-methoxytryptamin als kardioprotektives mittel